Prescribing Information
To view the full Prescribing Information for physicians or for patients, you need the Adobe® Acrobat® Reader®. Don't have the Adobe Acrobat Reader? You can download it for free.
To continue, choose one of the following:
I have Adobe Acrobat.
Show me the
Prescribing Information for physicians.
Show me the
Prescribing Information for patients.
I don't have Adobe Acrobat. I need to download it for free.
Adobe, Adobe Acrobat, and Adobe Acrobat Reader are either registered trademarks
or trademarks of Adobe Systems Incorporated in the United States and/or other countries.
AROMASIN® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with AROMASIN should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with AROMASIN should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and AROMASIN).
Copyright © 2009 Pfizer Inc. All rights reserved.
The product information provided in this site is intended only for residents of
the United States. The products discussed herein may have different product labeling
in different countries.
The health information herein is provided for educational purposes only and is not
intended to replace discussions with a health care provider. All decisions regarding
patient care must be made with a health care provider, considering the unique characteristics
of the patient.
AOU00471
